Rani Therapeutics Holdings, Inc. 8-K

What Happened
Rani Therapeutics Holdings, Inc. filed an 8‑K (Item 5.07) reporting the results of its annual meeting held May 28, 2026 (filed May 29, 2026). Stockholders voted to elect the company’s director nominees to serve until the 2027 annual meeting and to ratify CBIZ CPAs P.C. as the company’s independent registered public accounting firm for fiscal 2026. As of the record date (April 2, 2026) there were 99,812,515 shares of Class A common stock and 23,970,359 shares of Class B common stock outstanding; both classes vote together, one vote per share.

Key Details

• Annual Meeting date: May 28, 2026; 8‑K filed May 29, 2026 (Item 5.07).
• Outstanding shares (record date April 2, 2026): Class A 99,812,515; Class B 23,970,359.
• Director election vote totals (For / Withheld / Broker Non‑Votes):
  • Talat Imran: 57,336,620 / 148,439 / 19,921,604
  • Mir Imran: 56,592,898 / 892,161 / 19,921,604
  • Dennis Ausiello, M.D.: 57,356,662 / 128,397 / 19,921,604
  • Jean‑Luc Butel: 52,488,017 / 4,997,042 / 19,921,604
  • Vasudev Bailey, Ph.D.: 57,382,892 / 102,167 / 19,921,604
  • Abraham Bassan: 57,369,150 / 115,909 / 19,921,604
  • Lisa Rometty: 57,271,205 / 213,854 / 19,921,604
• Auditor ratification vote: CBIZ CPAs P.C. ratified — For: 77,019,828; Against: 332,645; Abstain: 54,190.

Why It Matters
The meeting result confirms the board composition for the coming year and continued oversight by the elected directors. Ratification of CBIZ CPAs P.C. establishes the independent accounting firm for Rani’s FY2026 audits and related financial reporting. Investors should note the presence of sizable broker non‑votes (~19.9 million) recorded across director elections; otherwise, the proposals were approved by the votes cast.